Famous Patents
In 1608, Dutch eyeglass maker Hans Lipperhey filed the first patent for a working telescope. The patent was denied.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7122375 | PRO274 nucleic acids The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 10/17/2006 |
| 7112657 | PRO697 polypeptides The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 09/26/2006 |
| 7098003 | PRO 1384 nucleic acids The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 08/29/2006 |
| 7071171 | Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2 compositions and uses thereof Novel genes expressed selectively by long-term dendritic cell (DC) lines (XS series) from murine epidermis which retain important features of resident epidermal Langerhans cells (LC) are provided. These genes encode distinct type II membrane-integrated polypeptides,... | 07/04/2006 |
| 7041646 | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders. ... | 05/09/2006 |
| 7041463 | Orthologues of human receptors and methods of use Methods for identifying modulators of receptor activity using orthologues of human receptors are described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided. The genes for bradykinin B1 | 05/09/2006 |
| 7026454 | Neuroendocrine marker of prostate cancer and method for producing same The present invention involves a novel neuroendocrine growth factor or marker (“NEM”) identified in cultured prostate cancer cells and conjugates of NEM and a binding agent capable of inhibiting binding of NEM to its receptor. ... | 04/11/2006 |
| 7009043 | Plus end-directed microtubule motor required for chromosome congression The invention provides isolated nucleic acid and amino acid sequences of Xenopus CENP-E (XCENP-E), antibodies to XCENP-E, methods of screening for CENP-E modulators using biologically active CENP-E, and kits for screening for CENP-E modulators. ... | 03/07/2006 |
| 6942978 | Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof The present invention provides a TADG-12 protein and a DNA fragment encoding such protein. Also provided is a vector/host cell capable of expressing the DNA. The present invention further provides various methods of early detection of associated ovarian and other ma... | 09/13/2005 |
| 6908619 | Camp factor of streptococcus uberis The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections. ... | 06/21/2005 |
| 6872568 | Death domain containing receptor 5 antibodies The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding... | 03/29/2005 |
| 6864066 | Epithelial protein lost in neoplasm (EPLIN) Polynucleotide and polypeptide sequences encoding a novel tumor suppressor protein, EPLIN, are provided. Also included is a method for detecting a cell proliferative disorder associated with EPLIN. EPLIN is a marker that can be used diagnostically, prognostically an... | 03/08/2005 |
| 6828429 | Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer A nucleic acid sequence that exhibits prostate-specific expression and over-expression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases.... | 12/07/2004 |
| 6818746 | Secreted and transmembrane polypeptides and nucleic acids encoding the same The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 11/16/2004 |
| 6818405 | Therapeutic use of the SMR1 protein and active derivatives thereof The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating disea... | 11/16/2004 |
| 6808930 | Therapeutic agents An agent comprising a protein complex comprising an oligomeric form of α-lactalbumin (MAL) and a further reagent which is combined with MAL such that it is carried into the nucleoplasm of cells which are susceptible to MAL. Agents of the type, where the further rea... | 10/26/2004 |
| 6797495 | Somatic cells with ablated PrP gene and methods of use The present invention comprises a method for producing mammalian therapeutics free from prion contamination and cells for use in such methods. Such therapeutics are produced in somatic cells having a genome with an artificially altered PrP gene. The PrP gene in thes... | 09/28/2004 |
| 6783986 | Sucrose phosphate synthetase (SPS), a preparation method and cDNA therefor, and use of the cDNA for modifying SPS expression in plant cells Proteins having the activity of saccharose phosphate synthetase (SPS) and a process for obtaining the same. ... | 08/31/2004 |
| 6770450 | Treatment and diagnosis of cancer The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate spe... | 08/03/2004 |
| 6770477 | Differentially expressed genes associated with HER-2/neu overexpression The present invention provides human Her-2/neu overexpression modulated proteins (HOMPS) and polynucleotides encoding HOMPS polypeptides. The invention also provides HOMPS containing expression vectors and host cells, HOMPS antibodies and methods of producing HOMPS.... | 08/03/2004 |
| 6770457 | Process of purifying angiogenesis inhibitors The present invention relates to process of purifying the angiogensis inhibitor proteins expressed in E. coli and to the use of recombinant kringle 1-3 (; greenstatin) purified by the above process as a angiogenesis inhibitor and an anticancer agent. Particul... | 08/03/2004 |
| 6767711 | Treatment and diagnosis of prostate cancer The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or ... | 07/27/2004 |
| 6767541 | HER-2/neu overexpression abrogates growth inhibitory pathways The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods for inhibiting the growth of cancer cells that exhibit certain genet... | 07/27/2004 |
| 6762283 | Caspase-8 interacting proteins There are provided proteins which interact with caspase-8. Production and use of such proteins is also provided. ... | 07/13/2004 |
| 6759204 | Method and kit for early diagnosis of cancer The invention concerns a method for early diagnosis of cancer in a patient which consists in identifying by any appropriate method the presence of autoantibodies directed against the Csk protein in a biological sample taken from said patient. The invention also conc... | 07/06/2004 |
| 6759043 | Monoclonal antibodies having property of causing apoptosis It is the objective and purpose of the present invention to provide a monoclonal antibody having the property of causing apoptosis on myeloid cells. This invention relates to a monoclonal antibody having the property of causing apoptosis on myeloid cells, and... | 07/06/2004 |
| 6749853 | Combined methods and compositions for coagulation and tumor treatment Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecif... | 06/15/2004 |
| 6746865 | Nucleic acids encoding for endostatin protein Nucleic acid sequences encoding for endostatin protein. Ribonucleic and deoxyribonucleic acid sequences that encode for endostatin protein are useful for gene therapy or recombinant expression for the treatment of angiogenesis-related diseases, specifically angiogen... | 06/08/2004 |
| 6743898 | Monoclonal antibodies that suppress B cell growth and/or differentiation The present invention provides monoclonal antibodies which interfere with the interactions between FDCs and B cells, thereby suppressing the proliferation and/or differentiation of B cells in lymphoid follicles. The monoclonal antibodies of the present invention are... | 06/01/2004 |
| 6743602 | Polynucleotides differentially expressed in adenocarcinomas, polypeptides encoded thereby, and methods of use thereof The present invention features human HX2004-6 polypeptide and nucleotide sequences encoding HX2004-6 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In related aspects the invention features expression vectors and ... | 06/01/2004 |
| 6740493 | Bone precursor cells: compositions and methods Disclosed are compositions of bone precursor cells and methods for their preparation and use. Bone precursor cells are cells which are not hematopoietic and which can differentiate into osteoblasts upon exposure to a bone growth factor and deposit calcium into the e... | 05/25/2004 |
| 6740516 | Nucleic acid and amino acid sequences An isolated nucleic acid sequence depicted in SEQ ID NO:6 is an alternative splice variant of human kallikrien-2 gene (KLK-2). An expression vector containing the splice variant and a host cell transfected by the expression vector are provided. The nucleic acid is u... | 05/25/2004 |
| 6740739 | Substitutional variants of APO-2 ligand A novel cytokine, designated Apo-2 ligand, which induces mammalian cancer cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibo... | 05/25/2004 |
| 6737259 | Modified arginine deiminase The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis. ... | 05/18/2004 |
| 6737397 | Control of cancer growth through the interaction of [MET5]-enkephalin and the zeta receptor The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor [Met5]-enkepha... | 05/18/2004 |
| 6734013 | Use of multivalent chimeric peptide-loaded, MHC/Ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy ch... | 05/11/2004 |
| 6733752 | Prevention of tumors with monoclonal antibodies against neu Prevention of transformation of a normal cell into a tumour cell in an individual at risk of developing a tumour having tumours which have p185 on their surfaces comprises: (a) identifying the individual and (b) administering to the individual an antibody which spec... | 05/11/2004 |
| 6733992 | Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof The present invention provides amino acid sequences of polypeptides that are encoded by genes within the human genome, the Ras-like protein polypeptides of the present invention. The present invention specifically provides isolated polypeptide and nucleic acid molec... | 05/11/2004 |
| 6730296 | Chimeric polypeptides containing chemokine domains This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof. ... | 05/04/2004 |
| 6727077 | Heregulin-like factor The present invention relates to a novel HLF protein which is a member of the heregulin family. In particular, isolated nucleic acid molecules are provided encoding the human HLF protein. HLF polypeptides are also provided as are vectors, host cells and recombinant ... | 04/27/2004 |
